Faron Pharmaceuticals Oy (DI) (FARN) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
16 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
16 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
16 Jan 2023 07:00 AM
RNS
Title: BEXMAB study update
23 Dec 2022 07:00 AM
RNS
Faron's Financial Calendar for 2023
05 Dec 2022 07:00 AM
RNS
BEXMAB Study Update
01 Dec 2022 07:00 AM
RNS
Faron Appoints Maija Hollmén PhD as CSO
18 Nov 2022 04:30 PM
RNS
Amendment Terms and Conditions with IPF Partners
02 Nov 2022 07:00 AM
RNS
Faron Announces Poster Presentation at SITC
31 Oct 2022 07:00 AM
RNS
BEXMAB Study Update
19 Oct 2022 09:20 AM
RNS
Holding(s) in Company
18 Oct 2022 12:30 PM
RNS
Holding(s) in Company
18 Oct 2022 07:00 AM
RNS
Faron Announces Melanoma Cohort Data from MATINS
14 Oct 2022 07:00 AM
RNS
Results of Placing
13 Oct 2022 05:31 PM
RNS
Proposed Issue and Placing of Shares
22 Sep 2022 07:00 AM
RNS
Grant of Options
20 Sep 2022 07:00 AM
RNS
Top-Line Data on Bexmarilimab Dose Variation
14 Sep 2022 07:00 AM
RNS
Faron to Host Bexmarilimab Update Webcast
13 Sep 2022 07:00 AM
RNS
Traumakine Data Presented at MHSR Symposium
07 Sep 2022 01:00 PM
RNS
Faron to Present at Upcoming Conferences
25 Aug 2022 07:00 AM
RNS
Faron Reports 2022 Half-Year Financial Results
08 Aug 2022 07:00 AM
RNS
Notice of Half-Year Financial Results
07 Jul 2022 09:45 AM
RNS
Results of EGM
30 Jun 2022 05:00 PM
RNS
Holding(s) in Company
28 Jun 2022 01:47 PM
RNS
Registration of New Shares
28 Jun 2022 07:00 AM
RNS
Announcement of Placing
16 Jun 2022 12:00 PM
RNS
Faron notice of EGM
15 Jun 2022 07:00 AM
RNS
Faron Announces Top-Line 12-Month Survival Results
08 Jun 2022 07:00 AM
RNS
First Patient Dosed in Ph I/II BEXMAB Combo Study
01 Jun 2022 07:00 AM
RNS
Exercise of options
30 May 2022 07:00 AM
RNS
Presentation of Biomarker Analysis at ASCO
16 May 2022 07:00 AM
RNS
FDA and FIMEA approve BEXMAB study to begin
12 May 2022 03:50 PM
RNS
Ex Vivo Data Presented at EHA2022 Congress
09 May 2022 07:00 AM
RNS
Mol Cancer Ther Publishes Bexmarilimab Research
04 May 2022 11:15 AM
RNS
Grant of options
22 Apr 2022 01:01 PM
RNS
Board Changes
22 Apr 2022 01:00 PM
RNS
Results of AGM
21 Apr 2022 04:30 PM
RNS
Faron Presents Melanoma Data at EADO
08 Apr 2022 03:45 PM
RNS
Managers' Transactions
05 Apr 2022 07:00 AM
RNS
Faron Closes HIBISCUS Trial
25 Mar 2022 09:00 AM
RNS
Notice of Faron Pharmaceuticals Ltd's AGM
25 Mar 2022 07:15 AM
RNS
Faron´s Annual Report 2021 Published
25 Mar 2022 07:00 AM
RNS
Financial Statement January 1 to December 31 2021
14 Mar 2022 07:00 AM
RNS
Faron Publishes Research From INTEREST Trial
09 Mar 2022 07:00 AM
RNS
Presentation of Biomarker Data at AACR 2022
07 Mar 2022 07:00 AM
RNS
Notice of 2021 Full-Year Results and Annual Report
04 Mar 2022 07:00 AM
RNS
Faron presents at upcoming conferences
28 Feb 2022 05:45 PM
RNS
Faron Board Issues Warrants to IPF Partners
28 Feb 2022 07:00 AM
RNS
Faron Obtains Debt Funding from IPF Partners
23 Feb 2022 07:00 AM
RNS
Faron Updates on Bexmarilimab Development Program
UK 100

Latest directors dealings